The federal government and states will face a number of challenges upon establishing and operating federally facilitated health insurance exchanges.
The federal government and states will face challenges in establishing and operating federally facilitated health insurance exchanges, according to a new Health Policy Brief from Health Affairs and the Robert Wood Johnson Foundation. Federal exchanges will be implemented in the 25 states that have elected to forgo running their own exchanges, as well as states that have decided to create and operate an exchange in partnership with the federal government.
One obstacle is the variation in state laws. It will be challenging for the Department of Health and Human Services (HHS) to customize exchanges to meet each state’s unique market needs, the policy brief says.
There is also an issue with states deciding not to expand Medicaid coverage. Without an expansion, people with incomes between 100% and 138% of the federal poverty level will be eligible to purchase coverage through exchanges, however those under 138%, who would have qualified for Medicaid with expansion, will not recieve subsidies because the law did not account for the possiblity of a state opt-out. Subsidized private coverage through an exchange will most likely cost more than Medicaid coverage, so the overall federal cost will be higher.
Additionally, the federal government will only be able to regulate plans that are sold through the exchanges, which is also potentially problematic. It runs the risk of healthy people opting for cheaper plans outside the exchange, while “sicker” people opt for exchange coverage. This increases the risk for adverse selection. Although there are risk-adjustment aspects to the Patient Protection and Affordable Care Act that could alleviate a plan’s gains and losses, they may not take effect right off the bat.
The timetable for the planning and implementation of these exchanges is also constricted. All exchanges must be ready for open enrollment, scheduled for October 2013, in order to be ready for the plan year that starts Jan. 1, 2014.
HHS has allowed states until the end of 2014 to obtain and use exchange establishment funding from the federal government, and it’s possible some states that initially decided to pass up creating their own exchange for an exchange partnership or federally facilitated model may replace those with an entirely state-run exchange.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More